Sign up Australia
Proactive Investors - Run By Investors For Investors

AusCann Group gets regulatory nod to supply medicinal cannabis products in Chile

Special access scheme will accelerate the plan to supply medicinal cannabis products.
medicinal cannabis products
Similar access scheme is used in Australia

AusCann Group Holdings Ltd (ASX:AC8) has achieved a major breakthrough following the establishment of a special access scheme which enables access for Chilean patients to medicinal cannabis products.

AusCann’s joint venture partner, Fundación Daya has worked with the Chilean National Institute of Public Health to establish the special access scheme.

READ: AusCann Group's vertically integrated model provides point of difference in medicinal cannabis industry

A similar access scheme is used in Australia, which enables doctors to prescribe cannabinoid medicines prior to product registration.

Second cannabis crop is getting ready for harvest

AusCann and Fundación Daya’s joint venture, DayaCann, is the only company in Chile to hold a medical cannabis production licence.

DayaCann has a proven growing record with the first crop yielding over 400 kilograms of dried cannabis in 2017.

The second crop has been planted and is scheduled for harvest this year.

Aiming to supply medicinal cannabis products for the treatment of pain

AusCann managing director Elaine Darby said: “We are delighted with the establishment of this special access scheme.

“DayaCann’s second crop is almost ready for harvest, and this special access scheme will accelerate the joint venture’s goal of producing and supplying final dose form medicines for the treatment of pain in the Latin American market”

READ: AusCann Group to collaborate in enhancing medicinal cannabis production

The new special access scheme (SAS) will be applied to a medical cannabis product being locally produced at Knop Laboratories from cannabis supplied by DayaCann.

The SAS allows patients to access the products whilst clinical trials for product registration are being completed.

The patients can apply to their doctors for a prescription, which will be approved by the public health department on a case-by-case basis.

Phase II pain management trial progressing in cancer patients

Phase I trials have been completed, and a phase II trial is being conducted for pain management in cancer patients at a Chilean public health centre.

The cannabinoid medicines being supplied under the SAS will be mainly accessed by patients of 15 municipalities who participated in the funding of earlier plantings by Fundación Daya.

As a result of this participation, a specified number of residents will receive free access to a year’s treatment.

Patients outside of these municipalities will be able to buy the products in pharmacies with their official permit approved by the Chilean National Institute of Public Health.

View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

lab
March 15 2018
Amryt's lead drug candidate, AP101, is a potential treatment for epidermolysis bullosa, a rare genetic skin disorder for which there is currently no approved treatment
Vial of pills
May 18 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
researcher filling a vial
April 24 2018
2018 is shaping up to be a crucial year for the company's drug pipeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use